XML 36 R26.htm IDEA: XBRL DOCUMENT
v3.26.1

INVESTMENTS (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2026
Debt Securities, Available-for-Sale [Abstract] |
Summary of Available-for-Sale Debt Securities at Estimated Fair Value | The following table summarizes our available-for-sale debt securities as of December 31, 2025:
|  | December 31, 2025
(in millions) |  | Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Estimated Fair Value
U.S. treasury securities |  | $ | 1,222 |  |  | $ | 3 |  |  | $ | — |  |  | $ | 1,224 |
U.S. government agencies securities |  | 15 |  |  | — |  |  | — |  |  | 15 |
Corporate debt securities |  | 1,392 |  |  | 7 |  |  | — |  |  | 1,398 |
Residential mortgage and asset-backed securities |  | 405 |  |  | 2 |  |  | — |  |  | 407 |
Total |  | $ | 3,033 |  |  | $ | 11 |  |  | $ | (1) |  |  | $ | 3,044 |
Summary of Classification of Equity Securities | The following table summarizes the classification of our equity securities on our Condensed Consolidated Balance Sheets, including certain equity method investments for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments:
(in millions) |  | June 30, 2026 |  | December 31, 2025
Equity securities measured at fair value: |  |  |  |
Cash and cash equivalents: |  |  |  |
Money market funds |  | $ | 1,563 |  |  | $ | 6,150 |
Prepaid and other current assets: |  |  |  |
Equity method investment in Lakefront Biotherapeutics NV (“Lakefront”) (formerly known as Galapagos NV) – fair value option |  | 500 |  |  | 551 |
Equity method investment in Arcus Biosciences, Inc. – fair value option |  | 969 |  |  | 749 |
Other equity method investments – fair value option(1) |  | 171 |  |  | 183 |
Other |  | 63 |  |  | 499 |
Other long-term assets |  | 431 |  |  | 386 |
Equity method investments and other equity securities without readily determinable fair values: |  |  |  |
Other long-term assets(2) |  | 295 |  |  | 393 |
Total |  | $ | 3,992 |  |  | $ | 8,909 |
________________________________ (1) Mostly comprised of our equity interest in Assembly Biosciences, Inc. (2) Mostly comprised of equity interests in certain collaboration partners and investment funds that are considered to be variable interest entities (“VIEs”) for which we are not the primary beneficiary. Our maximum exposure to loss as a result of our involvement in these VIEs is limited to the value of our investment.
Summary of Net Unrealized Gains and Losses on Equity Securities | The following table summarizes net unrealized gains and losses related to equity securities still held as of the respective ending balance sheet dates for the periods below, included in Other (income) expense, net on our Condensed Consolidated Statements of Operations:
|  | Three Months Ended |  | Six Months Ended
|  | June 30, |  | June 30,
(in millions) |  | 2026 |  | 2025 |  | 2026 |  | 2025
Unrealized (gain) loss, net, related to fair value option investments |  | $ | (289) |  |  | $ | (72) |  |  | $ | (143) |  |  | $ | 204 |
Unrealized (gain) loss, net, related to all other equity investments |  | (51) |  |  | (71) |  |  | 6 |  |  | 89 |
Total unrealized (gain) loss, net |  | $ | (340) |  |  | $ | (143) |  |  | $ | (137) |  |  | $ | 293 |

X
- References No definition available. + Details
Name: | us-gaap_AvailableForSaleSecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets. + References No definition available. + Details
Name: | us-gaap_MarketableSecuritiesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value. + References No definition available. + Details
Name: | us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of unrealized gains and losses on investments. + References No definition available. + Details
Name: | us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration